Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
HORIZON-PFT: Pivotal Fracture Trial
NCT00049829 · View on ClinicalTrials.gov ↗
Study Summary
HORIZON-PFT (Pivotal Fracture Trial) will study the effect of zoledronic acid, given once per year, on the treatment of osteoporosis in women past menopause. Hip and vertebral fractures are the most devastating consequences of osteoporosis. HORIZON-PFT is designed to determine the benefits of zoledronic acid in fracture reduction at both the hip and spine.
Conditions Studied
Interventions
- DRUG Zoledronic Acid
Study Locations (20)
California
- Osteoporosis Medical Center — Beverly Hills
- Orthopaedic Hospital — Los Angeles
- The Foundation for Osteoporosis Research and Education — Oakland
- University of California Davis- Gen Med Research — Sacramento
- Osteoporosis Prevention Center — San Diego
- Radiant Research- San Diego — San Diego
- Diablo Clinical Research, Inc — Walnut Creek
Florida
- CRA Research — Fort Lauderdale
- Anchor Research Center — Naples
- Sarasota Arthritis Center — Sarasota
- Radiant — Stuart
- Comprehensive Clinical Trials, LLC — West Palm Beach
Arizona
- Arizona Arthritis Research — Paradise Valley
- Southern Arizona VA — Tucson
Colorado
- Colorado Center for Bone Research — Lakewood
- Longmont Medical Research Network — Longmont
Alabama
- University of Alabama at Birmingham — Birmingham
Arkansas
- University of Arkansas for Medical Science — Little Rock
Connecticut
- Northeast Clinical Research — Hamden
Delaware
- Health Core — Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,700 participants |
| Start Date | 2002-01 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00049829
The ClinicalTrials.gov registry entry for NCT00049829 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 7,700 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 792 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Osteoporosis appearing as the primary indexed condition, and to 1 intervention — of which Zoledronic Acid is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00049829 reports 20 study locations spanning 8 distinct geographic areas — top geographies include California, Florida, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00049829 about?
NCT00049829 is a clinical study titled "HORIZON-PFT: Pivotal Fracture Trial". HORIZON-PFT (Pivotal Fracture Trial) will study the effect of zoledronic acid, given once per year, on the treatment of osteoporosis in women past menopause. Hip and vertebral fractures are the most devastating consequences of osteoporosis. HORIZON-PFT is designed to determine the benefits of zoledr...
What is the current status of trial NCT00049829?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7,700 participants. The study started on 2002-01.
What conditions does trial NCT00049829 study?
This clinical trial studies the following conditions: Osteoporosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00049829?
The interventions under investigation include: Zoledronic Acid (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00049829?
This trial is sponsored by Novartis Pharmaceuticals, which has 792 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00049829 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.